Nektar Therapeutics (NKTR) Expected to Announce Quarterly Sales of $26.22 Million

Share on StockTwits

Equities analysts forecast that Nektar Therapeutics (NASDAQ:NKTR) will post sales of $26.22 million for the current fiscal quarter, Zacks Investment Research reports. Five analysts have issued estimates for Nektar Therapeutics’ earnings, with estimates ranging from $21.15 million to $39.80 million. Nektar Therapeutics reported sales of $95.47 million in the same quarter last year, which would suggest a negative year-over-year growth rate of 72.5%. The company is scheduled to announce its next earnings report on Thursday, March 7th.

On average, analysts expect that Nektar Therapeutics will report full-year sales of $1.18 billion for the current financial year, with estimates ranging from $1.17 billion to $1.20 billion. For the next fiscal year, analysts forecast that the business will report sales of $457.12 million, with estimates ranging from $135.00 million to $1.18 billion. Zacks’ sales averages are an average based on a survey of sell-side research firms that cover Nektar Therapeutics.

Nektar Therapeutics (NASDAQ:NKTR) last announced its quarterly earnings results on Wednesday, November 7th. The biopharmaceutical company reported ($0.56) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.63) by $0.07. The company had revenue of $27.80 million during the quarter, compared to analyst estimates of $26.08 million. Nektar Therapeutics had a return on equity of 113.04% and a net margin of 59.71%. The firm’s revenue was down 81.8% on a year-over-year basis. During the same period in the prior year, the firm posted $0.37 earnings per share.

Several brokerages have recently weighed in on NKTR. ValuEngine raised Nektar Therapeutics from a “hold” rating to a “buy” rating in a research report on Tuesday, August 28th. Zacks Investment Research downgraded Nektar Therapeutics from a “hold” rating to a “sell” rating in a research report on Monday, October 22nd. Cowen set a $86.00 target price on Nektar Therapeutics and gave the stock a “buy” rating in a research report on Thursday. Piper Jaffray Companies set a $125.00 target price on Nektar Therapeutics and gave the stock a “buy” rating in a research report on Wednesday, July 25th. Finally, HC Wainwright set a $54.00 target price on Nektar Therapeutics and gave the stock a “hold” rating in a research report on Monday, October 22nd. Three research analysts have rated the stock with a sell rating, one has assigned a hold rating and ten have assigned a buy rating to the company’s stock. The stock presently has a consensus rating of “Buy” and an average target price of $79.55.

NASDAQ:NKTR traded down $1.29 on Friday, hitting $34.02. 2,896,498 shares of the stock were exchanged, compared to its average volume of 2,502,319. The firm has a market capitalization of $6.55 billion, a PE ratio of -61.85 and a beta of 2.91. The company has a debt-to-equity ratio of 0.13, a current ratio of 19.67 and a quick ratio of 19.55. Nektar Therapeutics has a fifty-two week low of $31.37 and a fifty-two week high of $111.36.

In other news, Director Dennis L. Winger sold 34,250 shares of the company’s stock in a transaction dated Tuesday, August 14th. The stock was sold at an average price of $60.60, for a total value of $2,075,550.00. Following the completion of the sale, the director now owns 59,875 shares of the company’s stock, valued at $3,628,425. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, Director Jeffrey Robert Ajer sold 6,750 shares of the company’s stock in a transaction dated Thursday, September 20th. The stock was sold at an average price of $56.76, for a total value of $383,130.00. Following the completion of the sale, the director now directly owns 15,750 shares of the company’s stock, valued at approximately $893,970. The disclosure for this sale can be found here. Insiders sold 96,000 shares of company stock valued at $5,825,680 in the last ninety days. Company insiders own 4.31% of the company’s stock.

A number of institutional investors and hedge funds have recently modified their holdings of the stock. BB Biotech AG boosted its holdings in Nektar Therapeutics by 61.0% in the third quarter. BB Biotech AG now owns 845,000 shares of the biopharmaceutical company’s stock valued at $51,511,000 after purchasing an additional 320,000 shares during the last quarter. Sterling Investment Advisors Ltd. purchased a new position in Nektar Therapeutics in the third quarter valued at about $183,000. American International Group Inc. boosted its holdings in Nektar Therapeutics by 13.1% in the third quarter. American International Group Inc. now owns 60,570 shares of the biopharmaceutical company’s stock valued at $3,692,000 after purchasing an additional 7,033 shares during the last quarter. BlackRock Inc. boosted its holdings in Nektar Therapeutics by 3.7% in the third quarter. BlackRock Inc. now owns 13,121,756 shares of the biopharmaceutical company’s stock valued at $799,902,000 after purchasing an additional 463,152 shares during the last quarter. Finally, Atlas Capital Advisors LLC boosted its holdings in Nektar Therapeutics by 1,015.3% in the third quarter. Atlas Capital Advisors LLC now owns 6,692 shares of the biopharmaceutical company’s stock valued at $360,000 after purchasing an additional 6,092 shares during the last quarter. 92.72% of the stock is owned by hedge funds and other institutional investors.

About Nektar Therapeutics

Nektar Therapeutics, a research-based biopharmaceutical company, discovers and develops drug candidates for cancer, auto-immune disease, and chronic pain in the United States. The company offers ONZEALD, a topoisomerase I inhibitor that is in Phase III clinical trial for advanced metastatic breast cancer in patients with brain metastases; NKTR-181, an orally-available mu-opioid analgesic molecule, which is in Phase III clinical trial for moderate to severe chronic pain; NKTR-214, a cytokine immunostimulatory therapy that is in Phase I/II to treat cancer; NKTR-358, which is in Phase I to treat autoimmune diseases; and NKTR-262 for solid tumors, as well as NKTR-255 that is under research/preclinical stage for immuno-oncology.

See Also: What is a Leveraged Buyout (LBO)?

Get a free copy of the Zacks research report on Nektar Therapeutics (NKTR)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Nektar Therapeutics (NASDAQ:NKTR)

Receive News & Ratings for Nektar Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nektar Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply